This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thorburn, C. E.
Right arrow Articles by Edwards, D. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thorburn, C. E.
Right arrow Articles by Edwards, D. I.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1998, p. 1973-1979, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Activities of Oral beta -Lactams at Concentrations Achieved in Humans against Penicillin-Susceptible and -Resistant Pneumococci and Potential to Select Resistance

Christine E. Thorburn,1,* Sarah J. Knott,1 and David I. Edwards2

SmithKline Beecham Pharmaceuticals, Brockham Park, Betchworth, Surrey RH3 7AJ,1 and Chemotherapy Research Unit, University of East London, London E15 4LZ,2 United Kingdom

Received 31 October 1997/Returned for modification 9 February 1998/Accepted 31 May 1998

The beta -lactam susceptibilities of 65 strains of Streptococcus pneumoniae for which penicillin MICs covered a broad range were assessed. The order of potency was amoxicillin (AMX) = amoxicillin-clavulanate (AMC) > penicillin G > cefpodoxime (CPO) > cefuroxime (CXM) > cefprozil > cefaclor > loracarbef > cefixime. No decrease in susceptibility was seen following repeated subculture of two penicillin-susceptible strains of S. pneumoniae in AMX, AMC, cefaclor, or loracarbef, whereas repeated exposure to CPO and CXM resulted in 4- to 32-fold decreases in susceptibility for both strains. When one of these strains was exposed to concentrations of CPO, CXM, AMX, and AMC achieved in the serum of humans following the administration of an oral dose, all agents were rapidly bactericidal, with no decrease in susceptibility up to 72 h. This was consistent with antibiotic concentrations exceeding the MICs for 100% of the dosing interval. For a penicillin-resistant strain, MICs were exceeded for 29% of the 12-h dosing interval for 500 mg of AMX, 42% of the interval for AMC with 875 mg of AMX and 125 mg of clavulanate (875/125 mg of AMC) 21% of the interval for 500 mg of CXM, and 0% of the interval for 200 mg of CPO. Consequently, only 875/125 mg of AMC produced a sustained bactericidal effect. A four- to eightfold reduction in susceptibility to CPO and CXM and cross-resistance with cefotaxime, but not penicillin or AMC, were selected following exposure to simulated serum CPO and CXM concentrations. In addition, AMX and AMC were the only agents which consistently produced a >99% reduction in bacterial numbers in time-kill studies using concentrations of antibiotic achieved in middle ear fluid for all three strains of penicillin-resistant S. pneumoniae tested.


* Corresponding author. Mailing address: c/o Tony White, Anti-infectives SPD, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (South), Third Avenue, Harlow, Essex CM19 5AW, United Kingdom. Phone: 01279 644373. Fax: 01279 646039.


Antimicrobial Agents and Chemotherapy, August 1998, p. 1973-1979, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Finlay, J., Miller, L., Poupard, J. A. (2003). A review of the antimicrobial activity of clavulanate. J Antimicrob Chemother 52: 18-23 [Abstract] [Full Text]  
  • Ball, P., Baquero, F., Cars, O., File, T., Garau, J., Klugman, K., Low, D. E., Rubinstein, E., Wise, R., Consensus Group on Resistance and Prescribing in R, T. (2002). Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 49: 31-40 [Abstract] [Full Text]  
  • Gustafsson, I., Lowdin, E., Odenholt, I., Cars, O. (2001). Pharmacokinetic and Pharmacodynamic Parameters for Antimicrobial Effects of Cefotaxime and Amoxicillin in an In Vitro Kinetic Model. Antimicrob. Agents Chemother. 45: 2436-2440 [Abstract] [Full Text]  
  • Perez-Trallero, E. (2000). Pneumococcal macrolide resistance--not a myth. J Antimicrob Chemother 45: 401-402 [Full Text]